Treatment of insulin-like growth factor deficiency with IGF-I: Studies in humans

Hormone Research

Volumn 65, Issue SUPPL. 1, 2006, Pages 21-27

  Backeljauw, Philippe F ^a   Chernausek, Steven D ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT SOMATOMEDIN C;

ADENOIDECTOMY; AIRWAY OBSTRUCTION; ANOREXIA NERVOSA; AUTOCRINE EFFECT; BODY FAT; CLINICAL FEATURE; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; EVALUATION; FACIAL NERVE PARALYSIS; FEEDING; GENE DELETION; HORMONE RELEASE; HORMONE SENSITIVITY; HUMAN; HYPOGLYCEMIA; INSULIN LIKE GROWTH FACTOR 1 DEFICIENCY; INTRACRANIAL HYPERTENSION; INTRACRANIAL PRESSURE; KIDNEY DEVELOPMENT; KIDNEY HYPERTROPHY; LIPOHYPERTROPHY; LIVER DISEASE; LIVER FAILURE; LYMPHATIC SYSTEM DISEASE; MIDDLE EAR EFFUSION; NONHUMAN; PARACRINE SIGNALING; PATIENT EDUCATION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REVIEW; RISK ASSESSMENT; SHORT STATURE; SNORING; SPLEEN SIZE; SPLENOMEGALY; TONSILLECTOMY;

ENDOCRINE SYSTEM; FEMALE; GROWTH DISORDERS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGLYCEMIA; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LIVER DISEASES; MALE;

EID: 33644612469     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090643     Document Type: Review

References (42)

1. Salmon WD Jr, Daughaday WH: A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957;49:825-836.
2. Laron Z: Natural history of the classical form of primary growth hormone (GH) resistance (Laron syndrome). J Pediatr Endocrinol Metab 1999;12(suppl 1):231-249.
3. Laron Z, Lilos P, Klinger B: Growth curves for Laron syndrome. Arch Dis Child 1993;68:768-770.
4. Savage MO, Blum WF, Ranke MB, Postel-Vinay MC, Cotterill AM, Hall K, Chatelain PG, Preece MA, Rosenfeld RG: Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome). J Clin Endocrinol Metab 1993;77:1465-1471.
5. Milward A, Metherell L, Maamra M, Barahona MJ, Wilkinson IR, Camacho-Hubner C, Savage MO, Bidlingmaier CM, Clark AJ, Ross RJ, Webb SM: Growth hormone (GH) insensitivity syndrome due to a GH receptor truncated after Box1, resulting in isolated failure of STAT 5 signal transduction. J Clin Endocrinol Metab 2004;89:1259-1266.
6. Hwa V, Little B, Adiyaman P, Kofoed EM, Pratt KL, Ocal G, Berberoglu M, Rosenfeld RG: Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b. J Clin Endocrinol Metab 2005;90:4260-4266.
7. Kofoed EM, Hwa V, Little B, Woods KA, Buckway CK, Tsubaki J, Pratt KL, Bezrodnik L, Jasper H, Tepper A, Heinrich JJ, Rosenfeld RG: Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med 2003;349:1139-1147.
8. Gluckman PD, Gunn AJ, Wray A, Cutfield WS, Chatelain PG, Guilbaud O, Ambler GR, Wilton P, Albertsson-Wikland K: Congenital idiopathic growth hormone deficiency associated with prenatal and early postnatal growth failure. The International Board of the Kabi Pharmacia International Growth Study. Journal of Pediatrics 1992;121:920-923.
9. Backeljauw PF, Underwood LE: Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab 2001;86:1504-1510.
10. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P: Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res 1999;51:128-134.
11. Klinger B, Laron Z: Three year IGF-I treatment of children with Laron syndrome. J Pediatr Endocrinol Metab 1995;8:149-158.
12. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L, Rosenfeld RG: Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. Journal of Clinical Endocrinology & Metabolism 1997;82:629-633.
13. Chemausek SD, Frane J, Bright GM, Underwood L, Group TGC: Efficacy of rhIGF-I in the treatment of chidlren with IGF I deficiency (IGFD) due to GH insensitivitiy (GHIS): 274 treatment years. Proceedings of the 7th Joint Meeting Paediatric Endocrinology 2005: Abstract P2-574.
14. Blethen SL, Compton P, Lippe BM, Rosenfeld RG, August, GP, Johanson A: Factors predicting the response to growth hormone (GH) therapy in prepubertal children with GH deficiency. Journal of Clinical Endocrinology and Metabolism 1993;76:574-579.
15. Chernausek SD, Bucuvalas, JC, Ritschel WR, Murray MM, Horn JA, Alfaro MP, Kuntze J, Martha PM: Comparative pharmacokinetics of rhIGF-I in children with growth disorders. Joint Meeting of the European Society for Pediatric Endocrinology and Lawson Wilkins Pediatric Endocrine Society, 1997.
16. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D: Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999;96:7324-7329.
17. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A: Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 2001;229:141-162.
18. Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J: Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev 1994;15:369-390.
19. Backeljauw PF, Kissoondial A, Underwood LE, Simmons KE: Effects of 4-years treatment with recombinant human inslulin-like growth factor I (RhIGF-I) on craniofacial growth in children with growth hormone inensitivity syndrome (GHIS). Hormone Research 1997;48:40.
20. Laron Z, Anin S, Klipper-Aurbach Y, Klinger B: Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 1992;339:1258-1261.
21. Leonard J, Samuels M, Cotterill AM, Savage MO: Effects of recombinant insulin-like growth factor I on craniofacial morphology in growth hormone insensitivity. Acta Paediatr Suppl 1994;399:140-141.
22. Guler H-P, Zapf J, Scheiwiller E, Froesch ER: Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc Natl Acad Sci USA 1988;85:4889-4893.
23. Backeljauw PF, Underwood LE: Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome - a clinical research center study. GHIS Collaborative Group. Journal of Clinical Endocrinology & Metabolism 1996;81:3312-3317.
24. Dunger DB, Cheetham TD: Growth hormone insulin-like growth factor I axis in insulin-dependent diabetes mellitus. Horm Res 1996;46:2-6.
25. Thrailkill KM, Quattrin T, Baker L, Kuntze JE, Compton PG, Martha PM Jr: Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group. Diabetes Care 1999;22:585-592.
26. Carroll PV, Umpleby M, Ward GS, Imuere S, Alexander E, Dunger D, Sonksen PH, Russell-Jones DL: rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM. Diabetes 1997;46:1453-1458.
27. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J: The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 2000;85:1518-1524.
28. Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons DR: Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996;45:91-100.
29. Kuzuya H, Matsuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T, Suzuki Y, Kobayashi M, Akazawa Y, Nomura M, et al.: Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 1993;42:696-705.
30. Backeljauw PF, Alves C, Eidson M, Cleveland W, Underwood LE, Davenport ML: Effect of intravenous insulin-like growth factor I in two patients with leprechaunism. Pediatr Res 1994;36:749-754.
31. Nakae J, Kato M, Murashita M, Shinohara N, Tajima T, Fujieda K: Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism. J Clin Endocrinol Metab 1998;83:542-549.
32. Levine RL: Endocrine aspects of eating disorders in adolescents. Adolesc Med 2002;13:129-143, vii.
33. Klibanski A, Biller BM, Schoenfeld DA, Herzog DB, Saxe VC: The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab 1995;80:898-904.
34. Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A: Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 2002;87:2883-2891.
35. Zhao G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike JW, Chernausek SD, Rosen CJ, Donahue LR, Malluche HH, Fagin JA, Clemens TL: Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 2000;141:2674-2682.
36. De Palo EF, Bassanello M, Lancerin F, Spinella P, Gatti R, D'Amico D, Cillo U: GH/IGF system, cirrhosis and liver transplantation. Clin Chim Acta 2001;310:31-37.
37. Bucuvalas JC, Cutfield W, Horn J, Sperling MA, Heubi JE, Campaigne B, Chernausek SD: Resistance to the growth promoting and metabolic effects of growth hormone in children with chronic liver disease. J Pediatr 1990;117:397-402.
38. Bucuvalas JC, Horn JA, Carlsson L, Balistreri WF, Chernausek SD: Growth hormone insensitivity associated with elevated circulating growth hormone-binding protein in children with Alagille syndrome and short stature. J Clin Endocrinol Metab 1993;76:1477-1482.
39. Chernausek SD, Underwood L, Kuntze J, Frane J, Bright GM: Safety of recombinant insulin-like growth factor I (rhIGF-I) in the treatment of children with IGF deficiency (IGFD) due to GH insensitivity: 231 treatment years of experience. Hormone Research 2004;64 (suppl 1):168.
40. Lordereau-Richard I, Roger M, Chaussain JL: Transient bilateral papilloedema in a 10-year-old boy treated with recombinant insulin-like growth factor I for growth hormone receptor deficiency. Acta Paediatr Suppl 1994;399:152.
41. Malozowski S, Tanner LA, Wysowski DK, Fleming GA, Stadel BV: Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone. J Pediatr 1995;126:996-999.
42. Rosenbloom AL, Berg MA, Kasatkina EP, Volkova TN, Skorobogatova VF, Sokolovskaya VN, Francke U: Severe growth hormone insensitivity (Laron syndrome) due to nonsense mutation of the GH receptor in brothers from Russia. J Pediatr Endocrinol Metab 1995;8:159-165.